TY - JOUR
T1 - Beyond pancreatic cancer
T2 - Irinotecan and gemcitabine in solid tumors and hematologic malignancies
AU - Rocha Lima, Caio Max S.
AU - Urbanic, James J.
AU - Lal, Asheesh
AU - Kneuper-Hall, Rayna
AU - Brunson, Chris Y.
AU - Green, Mark R.
N1 - Funding Information:
From the H. Lee Moffiu Cancer Center, Tampa, FL; and the Hollings Cancer Center, the Department of Medicine, HematologyOncology DIViSion, and the College of Medicine at the Medical UnllJersity of South Carolina, Charleston, SC. Drs Rocha Luna and Green have receit'ed research grant support from PharrnacUl Corp, EU uUy and Company, Aventis, and SmithKline Beecham. Dr Brunson has recellJed research grant support from Eli Ully and Company. Dr Kneuper-HaU has received research grant support from Eli Lilly and Company, Bristol-Myers Squibb, Notoarris, and Pharrnacia Corp. Address reprint requests to Caio Max S. Rocha Lima, MD, H. Lee Moffitt Cancer Center, Gf Program Office, lZ90Z Magnolia Dr, Tampa, FL 33612. Copyright © ZOO 1 by W. B. Saunders Company 0093-7754/01/2803-1006$35 .00/0 dol: 10. l053/sonc.2001 22534
PY - 2001/6
Y1 - 2001/6
N2 - Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge. Gemcitabine and irinotecan are well-tolerated single agents, each with a broad spectrum of antitumor activity. Preclinical data suggests synergy for the two drugs when used in combination. A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks. Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients. Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress.
AB - Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge. Gemcitabine and irinotecan are well-tolerated single agents, each with a broad spectrum of antitumor activity. Preclinical data suggests synergy for the two drugs when used in combination. A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks. Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients. Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress.
UR - http://www.scopus.com/inward/record.url?scp=0034892564&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034892564&partnerID=8YFLogxK
U2 - 10.1016/S0093-7754(01)80007-5
DO - 10.1016/S0093-7754(01)80007-5
M3 - Article
C2 - 11510032
AN - SCOPUS:0034892564
VL - 28
SP - 34
EP - 43
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
ER -